AKTOVEGIN 200MG N50 TB

AKTOVEQİN, film-coated tablets

Composition of Aktovegin

The composition of AKTOVEQİN contains 200.0 mg of blood components per 1 tablet: a deproteinized derivative of calf blood

Aktovegin, indications for use

As part of complex therapy: symptomatic treatment of cognitive disorders, including post-stroke cognitive impairment and dementia. Symptomatic treatment of disorders of peripheral blood circulation and their complications. Symptomatic treatment of diabetic polyneuropathy (DPN).

Contraindications

High sensitivity to the Aktovegin preparation and similar preparations or to excipients. Intolerance to fructose, glucose-galactose malabsorption, or sucrase-isomaltase deficiency. Children under 18 years of age.

Use during pregnancy and lactation

Aktovegin may be used only if the potential therapeutic benefit for the fetus or child outweighs the potential risk

Method of administration and dosage

For oral use, without chewing, before meals, with a small amount of liquid. Post-stroke cognitive impairment In the acute period of ischemic stroke, starting from day 5–7, by intravenous drip administration of 2000 mg per day for up to 20 infusions, then 2 tablets, 3 times a day (1200 mg/day). The total duration of treatment is 6 months. Dementia 2 tablets, 3 times a day (1200 mg/day). The total duration of treatment is 20 weeks. Disorders of peripheral blood circulation and their complications 1–2 tablets, 3 times a day (600–1200 mg/day). The duration of treatment is 4–6 weeks. Diabetic polyneuropathy 20 infusions with intravenous drip administration of 2000 mg per day, then 3 tablets, 3 times a day (1800 mg/day), treatment duration – 4–5 months.